Market research
RNO.AU Rhinomed Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 0.88
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU000000RNO1
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 0.88
About
About Rhinomed Limited
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RNO.AU discussion.
5 years, 5 months ago
Rhinomed Limited is currently in a long term uptrend where the price is trading 1.4% above its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
Rhinomed Limited's total revenue rose by 17.3% to $2M since the same quarter in the previous year.
Its net income has dropped by 3.5% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 37.7% to $-1M since the same quarter in the previous year.
Based on the above factors, Rhinomed Limited gets an overall score of 4/5.